Canada - English - Health Canada

marcan pharmaceuticals inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 25mg - quetiapine (quetiapine fumarate) 25mg - atypical antipsychotics

Canada - English - Health Canada

marcan pharmaceuticals inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 100mg - quetiapine (quetiapine fumarate) 100mg - atypical antipsychotics

Canada - English - Health Canada

marcan pharmaceuticals inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 200mg - quetiapine (quetiapine fumarate) 200mg - atypical antipsychotics

Canada - English - Health Canada

marcan pharmaceuticals inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 300mg - quetiapine (quetiapine fumarate) 300mg - atypical antipsychotics

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - quetiapine fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddy's laboratories australia pty ltd - quetiapine fumarate -

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 100 mg

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - quetiapine is indicated for the treatment of schizophrenia. the efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). the effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [ see clinical studies (14.1) ]. quetiapineis indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see clinical studies (14.2) ]. quetiapine is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. efficacy was established in two 8-week monotherapy trials in adul

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - 1.1 schizophrenia quetiapine is indicated for the treatment of schizophrenia. the efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). the effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see clinical studies (14.1)]. 1.2 bipolar disorder quetiapineis indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see clinical studies (14.2)]. quetiapine is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. efficacy was established in two 8-week monotherapy trials in adult patients with bipolar

Ireland - English - HPRA (Health Products Regulatory Authority)

g & a licensing limited - quetiapine fumarate - film coated tablet - 25 milligram